UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, cilt.17, sa.4, ss.120-123, 2018 (ESCI)
Objective: To reveal the association of side effect profiles seen in patients receiving intravesical bacillus Calmette-Guerin (BCG) immunotherapy for non-muscle-invasive bladder cancer (NMIBC) treatment with patient age and possible changes over time due to the use of different BCG strains.